Detail akcie arGEN-X SpADR online

Business Summary: argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, argenx SE - ADR revenues increased from $548.9M to $1.45B. Net income totaled $58.9M vs. loss of $101.5M. Revenues reflect Product net sales increase from $329.1M to $1.45B. Net Income reflects Financial income increase from $46.6M to $118.4M (income), Foreign Exchange Gain/Loss–Non-Business increase from $21.3M (expense) to $6.7M (income), Other Operating Income increase of 87% to $38.9M (income).